Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.

Statins may positively affect hepatocellular carcinoma risk in NAFLD patients

10 Oct 2019

Use of statins appears to reduce the risk of developing hepatocellular carcinoma (HCC) in patients with nonalcoholic fattly liver disease (NAFLD), whereas hypertension conferred a risk increase, according to a retrospective case-control study.

Researchers reviewed the medical records of 102 NAFLD patients (mean age, 69 years; 65 percent male) who underwent at least two computed tomography scans. Of these patients, 34 were HCC patients and 68 were matched non-HCC controls. NAFLD-HCC cases were confirmed on contrast imaging and/or biopsy.

The majority of the population had cirrhosis (91 percent). Multivariate logistic regression analysis showed statin use to be protective against HCC (odds ratio [OR], 0.20, 95 percent CI, 0.07–0.60; p=0.004), while hypertension was associated with a greater likelihood of HCC (OR, 5.80, 2.01–16.75; p=0.001).

On further analysis, visceral adipose tissue in males was higher before HCC development and decreased upon diagnosis in 86 percent, which was significantly different compared with controls (OR, 2.78, 1.10–7.44; p=0.04). Visceral adiposity at baseline was not a risk factor for HCC.

In a separate study, statins also exerted a beneficial inhibitory effect on HCC development, with the effect more pronounced in patients with liver cirrhosis or diabetes mellitus—conditions that are associated with a higher risk of HCC. [J Hepatol 2018;68:476-484]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.